Radiolabelled probes targeting tumor hypoxia for personalized medicine

Current Pharmaceutical Design

Volumn 20, Issue 14, 2014, Pages 2308-2318

  Mees, Gilles ^a   Sathekge, Mike ^b   Maes, Alex ^c,d   Van de Wiele, Christophe ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF PRETORIA   (South Africa)

^c Department of Nuclear Medicine AZ Groeninge ^*  (Belgium)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Hypoxia; Nitroimidazole; PET; SPECT

Indexed keywords

BRU59 21; FLUORINE 18; NITROIMIDAZOLE; OXO[3,3,9,9 TETRAMETHYL 1 (2 NITRO 1H IMIDAZOL 1 YL) 4,8 DIAZAUNDECANE 2,10 DIONEDIOXIMATO]TECHNETIUM TC 99M; TRACER; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; FLUORESCENT DYE; RADIOPHARMACEUTICAL AGENT;

CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER THERAPY; DRUG STRUCTURE; HUMAN; HYPOXIA; IMAGE ANALYSIS; IN VIVO STUDY; ISOTOPE LABELING; MEASUREMENT; MOLECULE; NEOPLASM; NON INVASIVE PROCEDURE; NONHUMAN; PERSONALIZED MEDICINE; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ANIMAL; ANOXIA; CHEMISTRY; DIAGNOSTIC USE; DRUG DELIVERY SYSTEM; NEOPLASMS; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; TRENDS;

ANIMALS; ANOXIA; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; FLUORESCENT DYES; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84903701593     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113196660662     Document Type: Review

References (136)

1. Vaupel P, Harrison L. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist 2004; suppl 5: 4-9.
2. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007; 26: 225-39.
3. Höckel M Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001; 93: 266-76.
4. Höckel M, Schlenger K, Aral B, Mitze M, Schäffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Research 1996; 56: 4509-15.
5. Fyles AW, Milosevic M, Wong R, et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiotherap Oncol 1998; 48: 149-56.
6. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiotherap Oncol 1996; 41: 31-9.
7. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiation Oncology Biol Phys 1997; 38: 285-9.
8. Nordsmark M, Bentzen SM, Rudat V, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiotherap Oncol 2005; 77: 18-24.
9. Brizel DM, Scully SP, Harrelson JM, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996; 56: 941-3.
10. 18F-fluoromisonidazole. Semin Nucl Med 2007; 37: 451-61.
11. Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J Nucl Med 2008; 49: 129S-48S.
12. Yang DJ, Wallace S, Cherif A, et al. Development of F-18-labeled fluoroerythronitromidazole as a PET agent for imaging tumor hypoxia. Radiology 1995; 194: 795-800.
13. Kubota K, Tada M, Yamada S, et al. Comparison of the distribution of fluorine-18 fluoromisonidazole, deoxyglucose and methionine in tumor tissue. Eur J Nucl Med 1999; 26: 750-7.
14. Rasey JS, Casciari JJ, Hofstrand PD, Muzi M, Graham MM, Chin LK. Determining hypoxic fraction in a rat glioma by uptake of radiolabeled fluoromisonidazole. Rad Res 2000; 153: 84-92.
15. Valk PE, Mathis CA, Prados MD, Gilbert JC, Budinger TF. Hypoxia in human gliomas: Demonstration by PET with fluorine-18-fluoromisonidazole. J Nucl Med 1992; 33: 2133-2137.
16. 18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiation Oncology Biol Phys 1996; 36: 417-28.
17. 18F-fluoromisonidazole and 15O-H2O. J Nucl Med 2004; 45: 1851-9.
18. 18F]fluoromisonidazole PET and pO2 electrode measurements. Acta Oncol 2002; 41: 304-12.
19. 18F-fluoromisonidazole PET and polarographic needle electrodes in human soft tissue tumors. Radiother Oncol 2003; 67: 339-44.
20. 18F]-2-fluoro-2-deoxyglucose). An appraisal of radiotherapeutically relevant hypoxia. Strahlenther Onkol 2004; 180: 616-22.
21. 18F]fluoromisonidazole and pO2-polarography in metastatic head and neck cancer. Eur J Nucl Med Mol Imaging 2006; 33: 1426-31.
22. 18F] fluorodeoxyglucose positron emission tomography: validated methods for the evaluation of therapy-relevant tumor oxygenation or only bricks in the puzzle of tumor hypoxia? BMC Cancer 2007; 7: 113-22.
23. 18F]fluoromisonidazole PET and immunohistochemistry. Br J Can 2004; 91: 1947-54.
24. 18F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors. Radiother Oncol 2006; 80: 157-64.
25. 18F]FMISO autoradiography and pimonidazole immunohistochemistry in human head and neck carcinoma xenografts. Eur J Nucl Med Mol Imaging 2008; DOI 10.1007/s00259-008-0772-7.
26. Hicks RJ, Rischin D, Fisher R, Binns D, Scott AM, Peters LJ. Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent. Eur J Nucl Med Mol Imaging 2005; 32: 1384-91.
27. 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 2005; 46: 253-60.
28. 18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients. Radiotherap Oncol 2006; 80: 151-6.
29. Rajendran JG, Schwartz DL, O'Sullivan J, et al. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res 2006; 12: 5435-41.
30. 18F]-Misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of trans-tasman radiation oncology group study 98.02. J Clin Oncol 2006; 24: 2098-104.
31. 18F-fluoromisonidazole PET, diffusionweighted MRI, and dynamic contrast-enhanced MRI. J Nucl Med 2009; 50: 1020-7.
32. 18F]-misonidazole positron emission tomography for head-and neck cancer patients undergoing concurrent chemoradiotherapy. Int J Radiation Oncology Biol Phys 2009; 75: 101-8.
33. 18F]fluormisonidazole uptake after neoadjuvant chemotherapy for head and neck squamous cell carcinoma. Mol Imaging Biol 2011; 13: 227-31.
34. 18F-FDG PET, and immunohistochemical studies. J Nucl Med 2006; 47: 410-8.
35. 18F] fluordeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study. BMC Cancer 2006; 6: 51-8.
36. 18Ffluoromisonidazole PET/CT study. J Nucl Med 2011; 52: 1048-55.
37. Thorwarth D, Eschmann SM, Paulsen F, Alber M. Hypoxia dose painting by numbers: a planning study. Int J Radiation Oncology Biol Phys 2007; 68: 291-300.
38. Lee NY, Mechalakos JG, Nehmeh S, et al. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomographyguided intensity-modulated radiotherapy for head and neck cancer: a feasibility study. Int J Radiation Oncology Biol Phys 2008; 70: 2-13.
39. Choi W, Lee SW, Park SH, et al. Planning study for available dose of hypoxic tumor volume using fluorine-18-labeled fluoromisonidazole positron emission tomography for treatment of the head and neck cancer. Radiother Oncol 2010; 97: 176-82.
40. Hendrickson K, Phillips M, Smith W, Peterson L, Krohn K, Rajendran J. Hypoxia imaging with [18F] FMISO-PET in head and neck cancer: Potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance. Radiother Oncol 2011; 101: 369-75.
41. 18F-fluoromisonidazole in head and neck cancer. Int J Radiation Oncology Biol Phys 2008; 70: 235-42.
42. Lin Z, Mechalakos J, Nehmeh S, et al. The influence of changes in tumor hypoxia on dose-painting treatment plans based on 8FFMISO positron emission tomography. Int J Radiation Oncol Biol Phys 2008; 70: 1219-28.
43. 18F]FETNIM: a potential hypoxia marker for PET. J Nucl Med 2001; 42: 1397-1404.
44. 18F]FMISO in an experimental mammary carcinoma. Eur J Nucl Med Mol Imaging 2004; 31: 513-20.
45. 18F-Fluoroerythronitromodazole radiation dosimetry in cancer studies. J Nucl Med 2002; 43: 1674-80.
46. 18F]fluoroerythronitromidazole PET. J Nucl Med 2001; 42: 1643-52.
47. Lehtiö K, Eskola O, Viljanen T, et al. Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-and-neck cancer. Int J Radiation Oncology Biol Phys 2004; 59: 971-82.
48. 18F-fluorodeoxyglucose positron emission tomography and prognostic value in locally advanced non-small-cell lung cancer. Clinical Lung Cancer 2010; 11: 335-40.
49. 18F-FETNIM PET in oesophageal squamous cell carcinoma: a pilot clinical study. Diseases of the Esophagus 2012; 25: 54-61.
50. Brown JM, Yu NY, Brown DM, Lee WW. SR-2508: a 2-nitroimidazole amide which should be superior to misonidazole as a radiosensitizer for clinical use. Int J Radiation Oncology Biol Phys 1981; 7: 695-703.
51. 18F]Fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia. J Nucl Med 1999; 40: 1072-9.
52. 18F]Fluoroetanidazole as a new marker for imaging tumor hypoxia with positron emission tomography. Cancer Res UK 2004; 90: 2232-42.
53. 18F]-EF1. Applied Radiation and Isotopes 1999; 51: 643-50.
54. 18F]EF1. J Nucl Med 2000; 41: 327-36.
55. 18F]-labeled EF3 [2-(2-nitroimidazol-1-yl)-N-(3,3,3-trifluoropropyl)-acetamide], a marker for PET detection of hypoxia. Bioorganic Med Chem 2001; 665-75.
56. 18F]EF3. Eur J Nucl Med Mol Imaging 2004; 31: 1263-72.
57. 18F]EF3 uptake on an individual mouse tumor basis. Eur J Nucl Med Mol Imaging 2006; 33: 553-6.
58. 18F]-FMISO in rodent tumor models. Radiother Oncol 2008; doi: 10.1016/j.radonc.2008.06.008
59. 18F]FMISO for PET-based hypoxia evaluation as measured in a rat rhabdomyosarcoma tumor model. Eur J Nucl Med Mol Imaging 2008; DOI 10.1007/s00259-008-x
60. 18F]EF3 in patients with head and neck tumors: a phase I study to assess the tracer pharmacokinetics, biodistribution and metabolism. Eur J Nucl Med Mol Imaging 2008; 35: 1282-9.
61. 18F]-EF5, a marker for PET detection of hypoxia: synthesis of precursor and a new fluorination procedure. Applied Radiation and Isotopes 2001; 54: 73-80.
62. 18F-EF5. Eur J Nucl Med 2003; 30: 259-66.
63. 18F-EF5 and positron emission tomography. BJU Int 2007; 99: 1154-60.
64. Koch CJ, Shuman AL, Jenkins WT, et al. The radiation response of cells from 9L gliosarcoma tumors is correlated with [F18]-EF5 uptake. Int J Radiat Biol 2009; 85: 1137-47.
65. Komar G, Seppänen M, Eskola O, et al. 18F-EF5: a new PET tracedr for imaging hypoxia in head and neck cancer. J Nucl Med 2008; 49: 1944-51.
66. 18F-EF5 uptake versus EF5 binding in human glioblastoma. Eur J Nucl Med Mol Imaging 2010; 37: 2048-59.
67. Mannan RH, Somayaji VV, Lee J, Mercer JR, Chapman JD, Wiebe LI. Radioiodinated 1-(5-iodo-5-deoxy-β-D-arabinofuranosyl)-2-nitroimidazole (iodoazomycin arabinoside: IAZA): a novel marker of tissue hypoxia. J Nucl Med 1991; 32: 1764-70.
68. Parliament MB, Chapman JD, Urtasun RC, et al. Non-invasive assessment of human tumor hypoxia with 123I-iodoazomycin arabinoside: preliminary report of a clinical study. Br J Cancer 1992; 65: 90-5.
69. Groshar D, McEwan AJB, Parliament MB, et al. Imaging tumor hypoxia and tumor perfusion. J Nucl Med 1993; 34: 885-8.
70. Urtasun RC, Parliament MB, McEwan AJ, et al. Measurement of hypoxia in human tumors by non-invasive spect imaging of iodoazomycin arabinoside. Br J Cancer Suppl 1996; 27: S209-S12.
71. Stypinski D, Wiebe LI, McEwan AJ, Schmidt RP, Tam YK, Mercer JR. Clinical pharmacokinetics of 123I-IAZA in healthy volunteers. Nuclear Med Communications 1999; 20: 559-67.
72. Stypinski D, McQuarrie SA, Wiebe LI, Tam YK, Mercer JR, McEwan AJB. Dosimetry estimations for 123I-IAZA in healthy volunteers. J Nucl Med 2001; 42: 1418-23
73. Kumar P, Ohkura K, Beiki D, Wiebe LI, Seki K. Synthesis of 1-β-D-(5-deoxy-5-iodoarabinofuranosyl)-2-nitroimidazole (β-IAZA): A novel marker of tissue hypoxia. Chem Pharm Bull 2003; 51: 399-403.
74. Zanzonico P, O'Donoghue J, Chapman JD, et al. Iodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning. Eur J Nucl Med Mol Imaging 2004; 31: 117-28.
75. 18F-MISO and 124I-IAZG PET in the same study cohort. Eur J Nucl Med Mol Imaging 2007; 35: 39-46.
76. Riedl CC, Brader P, Zanzonico PB, et al. Imaging hypoxia in orthotopic rat liver tumors with iodine 124-labeled iodoazomycin galactopyranoside PET. Radiology 2008; 248: 561-70.
77. Li XF, Sun X, Ma Y, et al. Detection of hypoxia in microscopic tumors using 131I-labeled iodo-azomycin galactopyranosside (131IIAZGP) digital autoradiography. Eur J Nucl Med Mol Imaging 2010; 37: 339-348.
78. Kumar P, Stypinski D, Xia H, McEwan AJB, Machulla HJ, Wiebe LI. Fluoroazomycin arabinoside (FAZA): Synthesis, 2H and 3Hlabelling and preliminary biological evaluation of a novel 2-nitroimidazole marker of tissue hypoxia. J Labelled Cpd Radiopharm 1999; 42: 3-16.
79. 18F-Fluoroazomycin arabinoside: a comparative study involving microPET, autoradiography, pO2-polarography, and fluorescence microscopy. Int J Rad Oncol Biol Phys 2008; 70: 1202-12.
80. Busk M, Horsman MR, Jakobsen S, et al. Can hypoxia-PET map hypoxic cell density heterogeneity accurately in an animal tumor model at a clinically obtainable image contrast? Radiother Oncol 2009; 92: 429-36.
81. 18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl Med Biol 2003; 30: 317-26.
82. 18F-Fluoroazomycin arabinoside. J Nucl Med 2005; 46: 106-13.
83. 18F]FAZA-first small animal PET results. J Pharm Pharmaceut Sci 2007; 10: 203-11.
84. 18F]FAZA PET in head and neck cancer patients: a pilot study. Eur J Nucl Med Mol Imaging 2007; 34: 1566-75.
85. 18F-FAZA). Eur J Nucl Med Mol Imaging 2009; 36: 1565-73.
86. 18FAZA) PET in the setting of MRI guided adaptive radiotherapy in cervical cancer. Acta Oncologica 2010; 49: 941-7.
87. 18F-FAZA PET/CT utilizing multi-modality fusion techniques. Eur J Nucl Med Mol Imaging 2011; 38: 1816-23.
88. 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine. J Nucl Med 2007; 48: 973-80.
89. Mortensen LS, Busk M, Nordsmark M, et al. Accessing radiation response using hypoxia PET imaging and oxygen sensitive electrodes: a preclinical study. Radiother Oncol 2011; 99: 418-23.
90. Grosu AL, Souvatzoglu M, Röper B, et al. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Int J Radiation Oncology Biol Phys 2007; 69: 541-51.
91. 18F]HX4: a phase I trial. Eur J Nucl Med Mol Imaging 2010; 37: 1663-8.
92. 18F-HX4 in monkeys and humans determined from whole-body PET/CT. Nucl Med Commun 2010; 31: 1016-24.
93. 18F]HX4, a promising hypoxia marker for PET imaging. PNAS 2011; 108: 14620-5.
94. Linder KE, Chan YW, Cyr JE, Malley MF, Nowotnik DP, Nunn AD. TcO(PnA. O-1-(2-nitroimidazole) [BMS-181321], a new technetium-containing nitroimidazole complex for imaging hypoxia: synthesis, characterisation, and xanthine oxidase-catalyzed reduction. J Med Chem 1994; 37: 9-17.
95. Kusuoka H, Hashimoto K, Fukuchi K, Nishimura T. Kinetics of a putative hypoxic tissue marker, technetium-99m-nitroimidazole (BMS181321), in normoxic, hypoxic, ischemic and stunned myocardium. J Nucl Med 1994; 35: 1371-6.
96. Shi CQX, Sinusas AJ, Dione DP, et al. Technetium-99mnitrimidazole (BMS181321): a positive imaging agent for detecting myocardial ischemia. J Nucl Med 1995; 36: 1078-86.
97. Rumsey WL, Kuczynski B, Patel B, et al. SPECT imaging of ischemic myocardium using a technetium-99m-nitroimidazole ligand. J Nucl Med 1995; 36: 1445-50.
98. Fukuchi K, Kusuoka H, Watanabe Y, Fujiwara T, Nishimura T. Ischemic and reperfused myocardium detected with technetium-99m-nitroimidazole. J Nucl Med 1996; 37: 761-6.
99. Ballinger JR, Kee JWM, Rauth AM. In vitro and in vivo evaluation of a technetium-99m-labeled 2-nitroimidazole (BMS181321) as a marker of tumor hypoxia. J Nucl Med 1996; 37: 1023-31.
100. Melo T, Duncan J, Ballinger JR, Rauth AM. BRU59-21, a secondgeneration 99mTc-labeled 2-nitroimidazole for imaging hypoxia in tumors. J Nucl Med 2000; 41: 169-76.
101. Zhang X, Melo T, Rauth AM, Ballinger JR. Cellular accumulation and retention of the technetium-99m-labelled hypoxia markers BRU59-21 and butylene amine oxime. Nucl Med Biol 2001; 28: 949-57.
102. Hoebers FJP, Janssen HLK, Olmos RAV, et al. Phase I study to identify tumor hypoxia in patients with head and neck cancer using technetium-99m BRU 59-21. Eur J Nucl Med 2002; 29: 1206-11.
103. Zhang X, Melo T, Ballinger JR, Rauth AM. Studies of 99mTc-BnAO (HL-91): a non-nitroaromatic compound for hypoxic cell detection. Int J Radiation Oncology Biol Phys 1998; 42: 737-40.
104. Honess DJ, Hill SA, Collingridge DR, et al. Preclinical evaluation of the novel hypoxic marker 99mTc-HL91 (prognox) in murine and xenograft systems in vivo. J Radiation Oncology Biol Phys 1998; 42: 731-5.
105. Iyer RV, Haynes PT, Schneider RF, Movsas B, Chapman D. Marking hypoxia in rat prostate carcinomas with β-D-[125I]azomycin galactopyranoside and [99mTc]HL-91: correlation with microelectrode measurements. J Nucl Med 2001; 42: 337-44.
106. Kinuya S, Yokoyama K, Li XF, et al. Hypoxia-induced alteration of tracer accumulation in cultured cancer cells and xenografts in mice: implications for pre-therapeutic prediction of treatment outcomes with 99mTc-sestamibi, 201Tl chloride and 99mTc-HL91. Eur J Nucl Med 2002; 29: 1006-11.
107. Lee BF, Chiu NT, Hsia CC, Shen LH. Accumulation of Tc-99m HL91 in tumor hypoxia: in vitro cell culture and in vivo tumor model. Kaohsiung J Med Sci 2008; 24: 461-72.
108. Siim BG, Laux WT, Rutland MD, Palmer BN, Wilson WR. Scintigraphic imaging of the hypoxia marker 99mTechnetium-labeled 2,2'-(1,4-diaminobutane)bis(2-methyl-3-butanone) dioxime (99mTclabeled HL-91; Prognox): noninvasive detection of tumor response to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Research 2000; 60: 4582-88.
109. Suzuki T, Nakamura K, Kawase T, Kubo A. Monitoring of response to radiation therapy for human tumor xenografts using 99mTc-HL91 (4,9-diaza-3,3,10,10-tetramethyldodecan-2,11-dione dioxime). Annals of Nuclear Medicine 2003; 17: 131-8.
110. Cook GJR, Houston S, Barrington SF, Fogelman I. Technetium-99m-labeled HL91 to identify tumor hypoxia: correlation with fluorine-18-FDG. J Nucl Med 1998; 39: 99-103.
111. Van de Wiele C, Versijpt J, Dierckx RA, et al. 99Tc(m) labelled HL91 versus computed tomography and biopsy for the visualization of tumor recurrence of squamous head and neck carcinoma. Nucl Med Commun 2001; 22: 269-75.
112. Li L, Yu J, Xing L, et al. Serial hypoxia imaging with 99mTc-HL91 SPECT to predict radiotherapy response in non small cell lung cancer. Am J Clin Oncol 2006; 29: 628-33.
113. Vavere AL, Lewis JS. Cu-ATSM: a radiopharmaceutical for the PET imaging of hypoxia. Dalton Trans 2007; DOI: 10.1039/b705989b
114. Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 1997; 38: 1155-60.
115. Dearling JLJ, Lewis JS, Mullen GED, Rae MT, Zweit J, Blower PJ. Design of hypoxia-targeting radiopharmaceuticals: selective uptake of copper-64 complexes in hypoxic cells in vitro. Eur J Nucl Med 1998; 25: 788-92.
116. Lewis JS, McCarthy DW, McCarthy TJ, Fujibayashi Y, Welch MJ. Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med 1999; 40: 177-83.
117. Burgman P, O'Donoghue JA, Lewis JS Welch MJ, Humm JL, Ling CC. Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM. Nucl Med Biol 2005; 32: 623-30.
118. Lewis JS, Sharp TL, Laforest R, Fujibayashi Y Welch MJ. Tumor uptake of copper-diacetyl-bis(N4-methylthiosemicarbazone): effect of changes in tissue oxygenation. J Nucl Med 2001; 42: 655-61.
119. Yuan H, Schroeder T, Bowsher JE, Hedlund LW, Wong T, Dewhirst MW. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med 2006; 47: 989-98.
120. 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: comparative study featuring microPET omaging, pO2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDU rat tumor models. Int J Radiation Oncol Biol Phys 2005; 61: 1493-502.
121. 18F]fluoromisonidazole positron emission tomography. Int J Oncol 2007; 30: 873-81.
122. 18FFLT and the hypoxic selective 64Cu-ATSM in a rodent model of cancer. Nuclear Med Biol 2008; 35: 713-20.
123. Dehdashti F, Mintun MA, Lewis JS, et al. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging 2003; 30: 844-50.
124. Dehdashti F, Grigsby PW, Mintun MA, Lewis JS, Siegel BA, Welch MJ. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report. Int J Radiation Oncol Biol Phys 2003; 55: 1233-38.
125. Dehdashti F, Grigsby PW, Lewis JS, Laforest R, Siegel BA, Welch MJ. Assessing tumor hypoxia in cervical cancer by PET with 60Culabeled diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med 2008; 49: 201-5.
126. Dietz DW, Dehdashti F, Grigsby PW, et al. Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. The ASCRS 2008; 51: 1641-8.
127. Minagawa Y, Shizukuishi K, Koike I, et al. Assessment of tumor hypoxia by 62Cu-ATSM PET/CT as a predictor of response in head and neck cancer: a pilot study. Ann Nucl Med 2011; 25: 339-45.
128. Chao KSC, Bosch Wr, Mutic S, et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensitymodulated radiation therapy. Int J Radiation Oncol Biol Phys 2001; 49: 1171-82.
129. Lewis JS, Laforest R, Dehdashti F, Grigsby PW, Welch MJ, Siegel BA. An imaging comparison of 64Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix. J Nucl Med 2008; 49: 1177-82.
130. Potter C, Harris AL. Hypoxia inducible carbonic anhydrase IX, marker of tumor hypoxia, survival pathway and therapy target. Cell Cycle 2004; 3: 164-167.
131. Lal A, Peters H, St Croix B, et al. Transcriptional response to hypoxia in human tumors. J Natl Cancer Inst 2001; 93: 1337-43.
132. Vordermark D, Kaffer A, Riedl S, et al. Characterization of carbonic anhydrase IX (CA IX) as an endogenous marker of chronic hypoxia in live human tumor cells. Int J Radiation Oncology Biol Phys 2005; 61: 1197-207.
133. Carlin S, Khan N, Ku T, Longo VA, Larson SM, Smith-Jones PM. Molecular targeting of carbonic anhydrase IX in mice with hypoxic HT29 colorectal tumor xenografts. PLos ONE 2010; 5: e10857.
134. Hoeben BAW, Kaanders JHAM, Franssen GM, et al. PET of hypoxia with 89Zr-labeled cg250-F(ab')2 in head and neck tumors. J Nucl Med 2010; 51: 1076-83.
135. Lawrentschuk N, Lee FT, Jones G, et al. Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and 124IcG250 PET/CT. Urol Oncol-Semin Ori 2011; 29: 411-20.
136. Thorwarth D, Alber M. Implementation of hypoxia imaging into treatment planning and delivery. Radiother Oncol 2010; 97: 172-5.